ADC Therapeutics S.A.
ADCT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $16,427 | $18,839 | $23,033 | $16,910 |
| % Growth | -12.8% | -18.2% | 36.2% | – |
| Cost of Goods Sold | $1,202 | $836 | $2,061 | $1,371 |
| Gross Profit | $15,225 | $18,003 | $20,972 | $15,539 |
| % Margin | 92.7% | 95.6% | 91.1% | 91.9% |
| R&D Expenses | $26,803 | $30,090 | $28,928 | $27,101 |
| G&A Expenses | $14,015 | $14,964 | $9,955 | $15,150 |
| SG&A Expenses | $19,014 | $18,969 | -$598 | $20,874 |
| Sales & Mktg Exp. | $4,999 | $4,005 | -$10,553 | $5,724 |
| Other Operating Expenses | $377 | $13,091 | $21,106 | $0 |
| Operating Expenses | $46,194 | $62,150 | $49,436 | $47,975 |
| Operating Income | -$30,969 | -$44,147 | -$28,464 | -$32,436 |
| % Margin | -188.5% | -234.3% | -123.6% | -191.8% |
| Other Income/Exp. Net | -$9,997 | -$11,245 | -$9,973 | $1,388 |
| Pre-Tax Income | -$40,966 | -$55,392 | -$38,437 | -$31,048 |
| Tax Expense | $0 | $1,254 | $165 | -$321 |
| Net Income | -$40,966 | -$56,646 | -$38,602 | -$30,727 |
| % Margin | -249.4% | -300.7% | -167.6% | -181.7% |
| EPS | -0.3 | -0.5 | -0.36 | -0.29 |
| % Growth | 40% | -38.9% | -24.1% | – |
| EPS Diluted | -0.3 | -0.5 | -0.36 | -0.29 |
| Weighted Avg Shares Out | 136,447 | 113,743 | 107,202 | 105,397 |
| Weighted Avg Shares Out Dil | 136,447 | 113,743 | 107,202 | 105,397 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,470 | $1,934 | $2,054 | $2,633 |
| Interest Expense | $13,392 | $12,997 | $12,230 | $11,919 |
| Depreciation & Amortization | $122 | $840 | $801 | $793 |
| EBITDA | -$27,452 | -$41,555 | -$25,687 | -$18,832 |
| % Margin | -167.1% | -220.6% | -111.5% | -111.4% |